Porky9: Well it’s looks like they went for it based on 25p. - What’s are they thinking ?
It is 0.25p (not 25p)
'nominal value 0.25 pence per ordinary share (the "Ordinary Shares")'.
BB
Bought more sub 26p - Bargain?????
BB
Tiziana Life Science (TLSA) did the same earlier last year, I believe, that was for $250m.
https://www.lse.co.uk/rns/TILS/tiziana-files-f-3-statement-with-us-sec-t5lp1kpa53j60hq.html
Haven't used it. Not sure if they can now as no longer ADR's - Full Nasdaq only listing.
BB
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_04122021_TLSA_Vandermosten.pdf
It seems so long ago now. They are talking about a valuation in 2027 just with Foralumab for MS & CD, I can wait. I also think that will be an underestimate, unless it includes major dilution.
BB
I'm good SK, just waiting for the $7.50 price target that was quoted last year to be hit!!!
BB
Original site - Acmsy = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $0.13
Newly created - ACUT = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $2.50
New listing - Probably testing the site before listing on Nasdaq!
See new website: https://accustem.com/investors/
that states: Accustem Sciences Inc started trading on the OTC under ACUT on March 2, 2022. For more investor information please contact us using our contact form or emailing us at investors@accustem.com
BB
Well put Phil.
I like the cut of your Jib!
BB
Thanks Rockz. Let's hope we've turned a corner with TLSA.
BB
The link to this presentation has already been posted:
https://myemail.constantcontact.com/Foralumab-Clinical-Update-in-Multiple-Sclerosis--A-Landmark-Study-with-Intranasal-Immunotherapy--hosted-by-Tiziana-Life-Sciences.html?soid=1127012015468&aid=MIH9XHuoSoE
Although there are only two people in the Individual Patient Expanded Access Program for SPMS, if (big if) the data can show the Blood, Brain barrier has been crossed, that could prove to be massive. The news flow for TLSA & ACUT appears to be ramping up. The $1 target for 10 consecutive day should be smashed. I hope no LTH's bailed at or around 60-70 cents, we are now 60+% off the low, but still priced to fail.
BB
Give us a hint please Rockz - It's not free access!
BB
Acmsy = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $0.13
ACUT = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $2.50
New listing - Probably testing the sight before listing on Nasdaq!
BB
20:1
The new price seems to be consolidated = $2.50
ACUT ticker
BB
The website looks a lot more professional.
BB
The two Companies have pretty much followed each other slide over the past 12 months.
TLSA is now +60%. Lets hope 4D can do the same and leave this Abyss.
BB
From SEC filing:
'On February 22, 2022, Tiziana Life Sciences Ltd. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department
(the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the
Company’s common shares had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq
Stock Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”).
The Notice has no immediate effect on the listing of the Company’s common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the
Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the
closing bid price of the Company’s common shares must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day
compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). The compliance period for
the Company will expire on August 22, 2022.
In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180
calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares
and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its
intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the
deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common shares will become
subject to delisting. In the event the Company receives notice that its common shares is being delisted, the Nasdaq Listing Rules permit the Company to
appeal any such delisting determination by the Staff to a Hearings Panel.
The Company intends to actively monitor the closing bid price of its common shares and is evaluating available options to regain compliance with the
Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the
Company will otherwise remain in compliance with the other listing standards for the Nasdaq Stock Market'
BB
When it suits the BOD's, Accustem had nothing to do with Tiziana Life Sciences anymore. This was stated to knock back shareholders from asking pressing questions. However, if it's a positive publication, lets push the information out there.
Let's see if the rise can be held onto. Highest close since the 10th Feb.
BB
Xenor: From Private placement RNS 17 Mar 21 - The Issue Price represents a discount of 16.3 per cent. to the closing price of £1.315 on 16 March 2021 (being the last practicable trading day prior to release of this Announcement).
At this price we are getting approximately a 77% discount (vis a vis my Risk/reward comment).
How much bad news has been received to change why those people invested money at £1.10?
BB
PG
That's why I started with £2, it would be laughed off. It's 600% from where we are now. Is $1bn enough? (£6 or £7)
BB
PG
It doesn't need to happen this year, if we raise money we are in a stronger negotiating position. Loads of permutations are an option.
Only my thoughts, but Merck could start buying at these levels and suddenly hold 15-20%. Allowing them to buy the other 80% at a higher level suitable to both sets of shareholders - £2???
I see the risk/reward at this level as excellent, but never a certified winner.
BB
The Cresh is now closed - Filter option active.
Pro's & Cons required for investing in 4d at this current time & price.
Pro's:
The risk reward has changed massively from 12 months ago when valued at £1.36
4D could be bought out, after announcing success in one trial
Con's
The company will probably need to raise money at some point this year. Unless buy out materialises.
BB